This is a clinical practice guideline on the use of accelerated partial-breast irradiation (APBI) as adjuvant radiation after breast-conserving surgery for patients with ductal carcinoma in situ and early-stage invasive breast cancer. The guideline provides recommendations regarding appropriate patient selection and techniques to deliver APBI. Patient selection criteria include age, tumour size, histology, estrogen receptor response, surgical margins, lymphovascular space invasion and nodal status. Efficacy and toxicity are considered with respect to recommendations for the appropriate and safe utilization of APBI.
We've listed guidelines under your selection of "Type of cancer". The most recent guidelines are first.
This is a clinical practice guideline on the role and appropriateness of fluorodeoxyglucose positron emission tomography - computed tomography (18F-FDG PET/CT) for initial breast cancer staging and its therapeutic and prognostic impact. Recommendations are stratified by risk, and outcomes of interest include sensitivity, specificity, change in stage compared to staging done by conventional imaging, prognosis, and costs. The guideline also addresses the association of metabolic information with biology and prognosis.
This is a clinical practice guideline for adult patients who may be at risk for developing breast cancer. The guideline examines breast cancer screening for this patient population at different levels of risk. Different screening options such as mammography, ultrasound, magnetic resonance imaging, and tomosynthesis are discussed.
This is a clinical practice guideline for the management of patients with advanced breast cancer (ABC), including those with locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). The guideline provides recommendations for the management of these patients, and specifically discusses the use of chemotherapy, management of bone metastases, management of cancer related fatigue, as well as supportive and palliative care.
This is a clinical practice guideline for patients undergoing treatment for breast cancer and for survivors of breast cancer. The guideline examines the use of complementary integrated therapies for the management of symptoms of disease as well as for the management of adverse effects associated with treatment. Recommendations are grouped within the following categories: acute radiation skin reaction, anxiety and stress reduction, chemotherapy-induced nausea and vomiting, depression and mood disturbances, fatigue, lymphedema, neuropathy, pain, quality of life, sleep disturbances, and vasomotor/hot flashes.
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline provides recommendations regarding interventions aimed at the promotion of skin health. Specific topics discussed include the promotion of skin hygiene, promotion of comfort, preventing infections, protection from trauma, and protection from the environment.
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the clinical assessment and management of these patients. Outcomes of interest include improved care delivery and quality of life, enhanced treatment compliance, as well as minimized patient burden regarding dressings (i.e. cost, frequency/difficulty of dressing changes).
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the management of long term effects, and provides recommendations on 1 month post-treatment and late reactions to promote cleanliness, treat the wound, prevent infections, protect from trauma and the environment, promote skin health and maintain skin flexibility.
This is a clinical practice guideline for women who are at increased risk of developing breast cancer. The guideline examines the elements of risk, risk assessment, risk-reduction interventions, and the components of risk-reduction counselling. Risk-reduction interventions considered are lifestyle modifications, risk-reduction surgery, and risk-reduction agents including Tamoxifen, Raloxifene, Aromatase, Anastrozole and Exemestane. Monitoring patients on risk reduction agents, and managing the side effects of these agents are also discussed.
This is a clinical practice guideline for women who have been diagnosed with or are at risk of developing breast cancer. The guideline examines the different methods of diagnosis and screening for breast cancer that will facilitate clinical decision-making. The guideline provides a consistent framework for screening and evaluating a spectrum of clinical breast lesions and takes into consideration different imaging modalities and screening recommendations for women at different levels of risk.